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Cyclosporine A-induced cell cycle arrest and cell death in renal quently, it has been proposed that the renal tubule is
epithelial cells. We studied the effects of cyclosporine A (CsA) also a direct target of CsA-induced renal injury [14]. We
on the proliferation of LLC-PK1 proximal tubule epithelial have previously shown, using an in vitro model system,cells. DNA damage was found to be an early event in CsA
that CsA is directly toxic to renal tubular cells in culturenephrotoxicity and could be a sensitive indicator of CsA injury
with a relative site selective action to the cells of thein renal epithelial cells. Cell cycle arrest induced by CsA was
coincident with elevated p53 levels. It is possible that trans- proximal tubular region of the nephron [15, 16]. The
activating p21 may mediate the halting of the cell cycle through exact cellular mechanisms of CsA-induced toxicity in
the CsA-induced accumulation of p53. renal tubule cells have not yet been established.
Cells respond to physiological or pathophysiological
stresses in a variety of ways, including adaptation, repair,
The introduction of the immunosuppressive agent or growth arrest. Cellular proliferation is a tightly regu-
cyclosporine A (CsA) as a therapeutic agent for organ lated process involving an ordered sequence of molecu-
rejection has revolutionized the field of clinical trans- lar events ensuring that, before division, cells have com-
plantation with improved allograft survival in kidney, pleted DNA replication and chromosome segregation
heart, liver, and pancreas transplantation [1, 2]. More [17]. Cell cycle progression is regulated through major
recent studies have also documented that CsA is effec- checkpoints located before the entry into the DNA syn-
tive in the treatment of autoimmune diseases, including thesis (S) phase and into the mitotic (M) phase [18–20].
systemic lupus erythematosus [3], psoriasis [4], and rheu- When cells receive an antiproliferative signal such as
matoid arthritis [5]. A major limiting factor in the use serum deprivation or exposure to DNA damaging
of CsA that still remains a significant problem and limits agents, a feedback control is activated that acts as a
its expansion into the field of autoimmune disease is brake on the cell cycle to inhibit progression through
nephrotoxicity [6]. Acutely, CsA may induce reversible these checkpoints [21].
reduction in renal blood flow and the glomerular filtra- In adult kidney, renal tubule cells are mostly in a
tion rate, whereas its chronic administration can lead to quiescent state and divide at a very slow rate. Tubular
irreversible renal failure, along with prominent tubuloin- cell proliferation can, however, be induced in response to
terstitial fibrosis [7, 8]. a number of physiological and pathophysiological stimuli
It is generally agreed that the acute renal hemody- [22, 23]. The proliferation of proximal tubule cells plays
namic effects of CsA may be mediated by an imbalance a key role in cell repair following toxic or ischemic injury
of vasoconstrictors and vasodilators [9]. However, clini- [24]. Growth arrest mediated by nephrotoxic agents
cal and experimental studies have demonstrated that could have implications for tubule cell regeneration, thus
CsA nephrotoxicity is also characterized by: (a) the accu- impeding the recovery from acute renal failure, and it
mulation of CsA in proximal tubular epithelial cells [10, may also contribute to the overgrowth of other cell types
11]; (b) cytoplasmic vacuolizations and swelling of the such as fibroblasts leading to interstitial fibrosis [25].
endoplasmic reticulum in tubular epithelial cells of the DNA-damaging agents cause cells to activate a variety
S3 segment of the proximal tubule [12]; and (c) extensive of stress response genes, which can transduce cell cycle
interstitial fibrosis with patchy tubular atrophy and thick- arrest through a number of different pathways. The tu-
ening of the tubular basement membrane [13]. Conse- mor suppressor protein p53 is now firmly established
as a key negative regulator of cell proliferation [26].
Recently, emphasis has been placed on the role of p53Key words: apoptosis, cell proliferation, CsA, nephrotoxicity, renal
injury. in arresting cells at the G1/S interface in response to
DNA damage [27]. However, it has also been postulated 1999 by the International Society of Nephrology
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Fig. 1. Flow cytometric analysis of the effect
of cyclosporine A (CsA) on the cell cycle of
LLC-PK1 cells. LLC-PK1 cells were treated in
the log phase of growth with CsA for 24 hours.
Control cells received vehicle (1% ethanol)
alone. Cell suspensions were fixed in 70% eth-
anol for 30 minutes at 48C. Cells were then
incubated in 40 mg/ml propidium iodide (PI)
in the presence of 100 mg/ml RNAase A for
30 minutes at 378C. Analysis was carried out
on a FACStar plus flow cytometer (Becton
Dickinson, Mountain View, CA, USA) with
laser excitation at 488 nm using a band pass
filter to collect red PI fluorescence. Nonviable
cells were gated out of analysis on the basis
of size and granularity, and only viable cells
were included in the results. The percentages
of cells in the various phases of the cell cycle
were analyzed using Macintosh CELLQUEST
software. Ten thousand events (cells) are rep-
resented in each histogram.
that p53 has a regulatory role at other cell cycle check- control: G1 phase 62 6 3% to 78 6 2%; S phase 14 6
2% to 7 6 1%; G2/M phase 17 6 2% to 8 6 1%. Atpoints [28].
We have investigated the effect of CsA on the prolifer- higher CsA doses (21 to 42 mm), cells were arrested in
the G2/M phase as indicated by the following percentagesation of LLC-PK1 proximal tubule epithelial cells. In
actively dividing LLC-PK1 cells, CsA caused significant in phases of the cell cycle with 42 mm CsA: G1 phase 59 6
1%; S phase 1.5 6 0.5%; and G2/M phase 32 6 1. Duringinhibition of DNA synthesis (as assessed by incorpora-
tion of 3H-thymidine) in a time- and dose-dependent the flow cytometric analysis of cell cycle, nonviable cells
were gated out of the analysis on the basis of light scattermanner. Twenty-four–hour treatment with 4.2 mm CsA
reduced 3H-thymidine incorporation to 52.7 6 1.6% of (indicative of cell size and cellular granularity), and only
viable cells were included in the results.control (P , 0.05). DNA synthesis was inhibited as early
as four hours and occurred before losses in cellular viabil- Coincident with CsA-induced alterations in the cell
cycle of LLC-PK1 cells, CsA treatment produced dose-ity were detected by either 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenytetrazolium (MTT) incorporation or Neutral dependent elevations in p53 protein expression. Scan-
ning densitometry of Western blots indicated p53 levelsRed uptake assays. This would indicate DNA damage
as an early event in CsA nephrotoxicity and a sensitive to be 163 6 9% of control following 24 hours of treat-
ment with 4.2 mm CsA. Western blot analysis of p53 levelsindicator of CsA injury in renal epithelial cells. Flow
cytometric cell cycle analysis indicated that the observed were supported by flow cytometric immunofluorescence
where p53 levels were also found to be elevated signifi-reduction in DNA synthesis was caused by a cell cycle
arrest (Fig. 1). CsA caused a dose-dependent depletion cantly. These results suggest that CsA induced DNA
damage in LLC-PK1 cells, dose dependently halting pro-in S-phase cells, supporting the thymidine results. At
doses of up to 21 mm, this was paralleled by an increase gression through the cell cycle at either the G1/S or G2/M
checkpoints. This cell cycle arrest would appear to bein the percentage of cells in the G1 phase. For example,
a 24-hour treatment with 4.2 mm CsA induced the follow- mediated at least in part through the accumulation of
p53 protein.ing percentages in phases of the cell cycle compared with
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Review of the literature shows that cellular DNA dam- trans-activation of p21 mediates the halting of the cell
age induces a variety of molecular responses, including cycle following CsA-induced p53 accumulation. It is pos-
the synthesis, activation, or inhibition of proteins that sible that in these renal epithelial cells, the induction
halt the progression through the cell cycle or mediate of p21 is transduced by CsA through p53-independent
cell death. The tumor suppressor protein p53 is induced pathways as well as p53-dependent pathways simultane-
following DNA injury and is crucial in this cellular re- ously in response to DNA injury [37]. The mechanisms
sponse by trans-activation of a number of genes. It is underlying the cell cycle arrest in the G1 phase at low-
estimated that there are as many as two hundred p53- dose CsA (4.2 mm) and in the G2/M phase at high-dose
regulated genes in the human genome [29], many of CsA (21 to 42 mm) require further investigation.
which play a role in cell cycle control. Upon DNA injury,
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nine kinases termed cyclin-dependent kinases (CDKs)
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